Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05925114 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of S-309309 in Obese Adults
A Phase 2 study, sponsored by Shionogi.
- Completed
- Registry status
- Phase 2
- Development phase
- 365
- Enrollment target
NCT05925114: Completed Phase 2 study, sponsored by Shionogi.
NCT05925114 is a Phase 2 study that has completed, run by Shionogi. The registered enrollment target is 365 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (174% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05925114, a Phase 2 study, has completed, sponsored by Shionogi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 365 participants
- Enrollment target
Study Summary
The primary objective of this study is to understand the efficacy of S-309309 on the body weight of obese adults.
Interventions
- DRUG Placebo
- DRUG S-309309
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 365 participants |
| Start Date | 2023-06-21 |
| Est. Completion | 2024-05-17 |
| Phase | Phase 2 |
What the finished NCT05925114 record still lists
NCT05925114 is an interventional study that assigns participants to a tested intervention. The registered 365 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (174% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05925114 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05925114 about?
NCT05925114 is a clinical study titled "Safety and Efficacy Study of S-309309 in Obese Adults". The primary objective of this study is to understand the efficacy of S-309309 on the body weight of obese adults.
What is the current status of trial NCT05925114?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 365 participants. The study started on 2023-06-21. Estimated completion is 2024-05-17.
What interventions are being tested in trial NCT05925114?
The interventions under investigation include: Placebo (DRUG), S-309309 (DRUG).
Who is sponsoring clinical trial NCT05925114?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05925114's enrollment target sits among peer trials
365 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04049604 · 365 participants · NA
IDENTIFY Study: Natural History of Maternal Neoplasia
- NCT05065840 · 365 participants · NA
Advancing HPV Vaccination Among HIV Positive Adults: The CHAMPS Study
- NCT05303519 · 365 participants · Phase 3
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- NCT05592626 · 365 participants · Phase 1
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI